An Open Label, Single-group, Multicenter Study on the Efficacy and Safety of Leuprolide Acetate 45 mg for Injectable Suspension-controlled Release in Subjects With Central (Gonadotropin-dependent) Precocious Puberty
Latest Information Update: 21 Apr 2025
At a glance
- Drugs Leuprorelin (Primary)
- Indications Precocious puberty
- Focus Therapeutic Use
- Acronyms NEST
- Sponsors HanAll Biopharma
Most Recent Events
- 21 Apr 2025 New trial record